SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance

By Baranck M.   Bohacova V.   Kvackajova J.   Hudecova S.   Krizanova O.   Breier A.  

European Journal of Pharmaceutical Sciences, Vol. 14, Iss. 1, 2001-08 ,pp. : 29-36

Elsevier

Access to resources Recommend Favorite

The ERK/MAPK pathway, as a target for the treatment of neuropathic pain

By Ma Weiya   Quirion Remi  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 4, 2005-08 ,pp. : 699-713

Informa Healthcare

Access to resources Recommend Favorite

The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 823-833

Bentham Science Publishers

Access to resources Recommend Favorite

The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies

By  

Current Cancer Drug Targets, Vol. 6, Iss. 8, 2006-01 ,pp. : 671-679

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of genes across the doxorubicin pathway

By Jamieson David   Boddy Alan V  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 10, 2011-10 ,pp. : 1201-1210

Informa Healthcare

Access to resources Recommend Favorite